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CORKUNICATION  FROR  TH!  COHHISSIOM  TO  !HI COUNCIL 
CONCERNING  THE  USE  OF  CERTAIN  SUBSTANCES 
HAVING  A HORMONAL  ACTION  IN  ANIMAL  PRODUCTION 
GENERAL 
1. In order to protect the health of  the  consumer;  in October 1980  the 
Commission  proposed  (Com  (80)  614  Pinal)  to  the Council  that the use  on 
domestic  animals  of substances with oestrogenic,  androgenic  and  gestagenic 
effects should be  prohibited,  except for  the  therapeutic use  of natural 
hormonal  substances(!}. 
2.  On  31  July 1981  the Council  adopted Directive 81/602/I!C concerning  the 
prohibition of certain substances having  a  hormonal  action and  of any 
substances having  a  thyrostatic action<2>.  Subsequently,  in 
February 1983,  to take account of this decision,  the Council  amended 
Directive 64/433/I!C  on  health problema  affecting intra-Community  trade  in 
fresh meat(3)  and  Directive 72/462/B!C  on  health and veterinary 
inspection problems  upon  importation of bovine  animals  and  swine  and  fresh 
meat  from  Third Countries<•>. 
With  its first decision,  the Council  agreed with  the general  approach  of 
the Commission  and  decided on  the urgent need  to prohibit the marketing of 
stilbenes,  stilbene derivatives.  their salts and esters and  tbyrostatie 
substances tor administering  to animals of all species. 
However,  it did not  take a  decision concerning the administering  to  farm 
animals  of Oestradiol 178,  Progesterone.  Testosterone,  Trenbolone  and 
Zeranol for fattening purposes.  l'be,CoDDiasion  undertook to further 
consult  the  competent scientific co11111ittees  on  this guestion and  to make  a 
further proposal  to the Council. 
(1)  OJ  No  C 305  of 22.11.1980,  p.  2 
(2)  OJ No  L222  of 7.8.1981,  p  32 
(3)  OJ  No  L  59  of 5.3.1983,  p  10 
(4)  OJ  No  L 59  of 5.3.1983,  p  34 - 2  -
HEALTH  ASPECTS 
3.  To  this end  the Commission  asked  the opinions of the Sclentlfle Vetarinarr 
Committee,  the Scientific Committee  for Animal  Nutrition  and  the Scientific 
Coamittee for Food.  To  further this wort a Scientific Group  on  Anabolic 
A&ents  in Animal  Production studied the matter;  their report vas  the basis 
for the  work  of  the  co~mittees.  The  result  of  these  consultations  is 
annexed  to  this  communication. 
4.  The  Scientific Committees  were  in ceneral acrea.ent with  the conclusions 
and  reco.maendations  of the Scientific Group,  namely: 
•fbe Scientific Vortin&  Group  is of the opinion  that the use of  Oestrad~ol 
178,  Testosterone and  Pro&esterone  and  those derivatives wblch  readilr 
rield the parent compound  on  hrdrolrsis after absorption  from  the alta of 
application, would  not present anr haratul effects to the health of tbe 
consumer  wben  used under  the appropriate conditions as  growth  promoters  in 
farm  aniaala.• 
!valuation of the data on  •trenbolone•  an4  •zeranot•  revealed that some 
data on  tbe hormonal  non-effect level and  the toxicolO&J  of  these compounds 
and  their ..  tabolites are still missing. 
The  Scientific Verkin&  Group  conaiders it necesaarr that additional 
information be  provided before a  final conclusion can  be  &iven  on 
trenbolone and  zeranol. 
Proper pro&raames  to control and monitor the use of anabolic &&ants  are 
essential. 
It is neceasarr to continue scientific investi&ationa on  the relevance or 
'  the present use of the  •no-hormone  effect• level when  related to the 
bar.ful effects of anabolic acents. 
.1. 
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5.  The  Commission  finds  no  reason  to disagree  with  with  the  findings  of 
its Scientific  Committees. 
The  Commission  accepts  that  the  Committees  studied  the question on  the 
basis  of  the  latest  advances  in  scientific  knowledge  in  the  matter of 
toxicity  including  the  biological  aspects.  It  in particular notes  the 
observations  to  the  effect  that  as  regards  the  natural  hormones  <endogenous). 
-humans  are daily  producing  high  quantities  of  oatural 
hormones  ; 
- humans  are  regularly  exposed  to  higher  and  widely  variable 
levels  of  natural  hormones  in  food  from  untreated animals  ; 
- the  human  liver  and  placenta  present effective tissue barriers 
to  the  residues  of  natural  hormones  which  may  be  present  in the 
tissue of  treated animals  ; 
Thus  no  question of  safety arises  in  relation  to the proper  use 
of  Oestradiol  17 p,  testosterone and  ~rogesterone in an 
appropriate  form 
6.  The  Commission  takes  into account  the  advice  of  Community  Scientific opinion 
that  the  use  of  Oestradiol  17  p,  Testosterone  and  Progesterone  and  those 
derivntives  which  readily yield the  parent  compound  after absorption  from 
the  site of  application,  would  not  present  any  harmful  effects  to  the 
health  of  the  consumer  when  used  under  appropriate  conditions  as  growth 
promoters  in  farm  animals. 
7.  In  addition  the  Commission  accepts  the  need  for  the authorisation of 
any  substances  to  be  subject to  the  establishment  of  proper  conditions 
of  use,  including specification of  the doses,  the  type  of  pharmaceutical 
preparation,  the  number  and  frequency  of administrations,  the association 
of  anabolic agents,  localisation of  implant  and  ablation  of  the  zone 
treated and  the delay period  before  the  animal  may  be  slaughtered. 
These  conditions  must  be  established to  supplement  the existing criteria 
in  relation to veterinary medicines,  and  should  be  established by  a 
Community  procedure. - 4  -
The  Commission  considers  that  the basis  for  the  establishment  of  these  criteria 
is already  provided  for  in the  Council  Directives 81/851/EEC  of  28  September  1981 
on  the  approximation of  the  laws  of  the  Member  States  relating  to veterinary medical 
products  and  81/852/EEC  of  28  September  1981-on  the approximation  of  the  laws  of 
the Member  States  relating to analytical,  pharmaco-toxicological  and  clinical 
standards  and  protocols  in  respect  of  the  testing of veterinary medical  products 
and  that  any  authorisation of substances  must  be  subject  to the  full  implementation 
in all Member  States of  the principles established in these  Community  texts. 
8.  Scientific opinion  in the  Community  considers  it necessary  to obtain supplementary 
information before  giving a  final  conclusion on  trenbolone and  zeranol.  In 
these  circumstances,  the  Commission  may  not  propose  the  continued use  of  these 
substances  in the  Community  as  long  as it has  not  been  shown  that  they are  without 
danger.  For  the moment  it proposes  that  they are banned.  It is evident  that it 
will  submit  any  possible  new  data  on  these products  or  on  any  new  substances,  to 
the advice of  the Scientific Veterinary Committee,  the Scientific Committee  for 
Animal  Nutrition ·and  the Scientific Committee  for  Food.  It will  also  consult 
the  numerous  interested parties on  the  subject and  in particular the  consumers 
within  the  Veterinary Advisory  Committee and  will  inform  the  Consumers  Advisory 
Committee. 
9.  The  need  for  the  Community  to  continue  to  follow  the  most  modern  scientific 
developments  and  investigations  in this field is  c_lear.  The  Commission  will 
support  such  work  wherever  possible,  so  that it may  make  any  proposals  necessary 
to take  new  developments  into account. 
ECONOMIC  ASPECTS 
10.  The  Commission  services  have  studied available  information as  regards  the  economic 
benefit  to  the producer and  consumer  that  may  result  from  the safe use  of 
authori~ed anabolic  substances. 
This  information  included,  in particular,  the proceedings  of  a  workshop  held 
in Brussels 5th-6th March  1981  on  anabolic agents  in beef and  veal  production, 
under  the auspices of the  division for  the  co-ordination of agricultural 
research  of  the  European  Commission(1);  the  joint  FAO/WHO  expert  committee  on 
food  additives  (JECFA)  which  was  convened  in Geneva  23  March- 1  April  1981; 
and  the  symposium  organised by  the  International Office  of  Epizootice  (O.I.E.) 
on  anabolics  in animal  production  in Paris 15th-17th  February  1983. 
(1)  IBSN-0-905442-54-7 
•  .. 
• 
~ . 
~ 
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The  conclusions  in all  cases  agree that  there  is  a  significant benefit to 
be  gained by  the  safe  use  of  anabolic agents.  Benefit arising  from  the 
clear  increases  in the  daily weight  gains  of  most  classes  of  animals  under 
various  systems  of  fattening;  gains  in  carcase weight,  and  in particular 
significant  increase  in  the  efficiency of  feed  conversion  into  meat.  The 
latter  is of particular  importance  as  regards  avoiding  wastage  of  feed 
resources  and  also preventing  escalation  of  the  price  of  meat  to  the  consumer • 
If an  average  benefit of  10%  is  allowed  for,  the  extra  feed  needed  for  food 
production  would  be  a  notable  economic  burden ·on  the population of those states 
not  taking  advantage  of this safe aid  to animal  production. 
QUALITY  ASPECTS 
11.  The  Commission  services at the  same  time  as  examining  the  information available 
on  the  economic  aspects  of  the  use  of anabolics  has  also  examined  the quality 
aspects,  in particular as  far as  the  three natural  substances  are  concerned. 
Due  to  the  influence it has  on  the physiological and  anatomical  development 
of  animals,  there  is  an  indication that  certain quality factors  may  be 
improved;  such  as  the  composition of  the  tissues of  the  carcase,  especially 
an  advantageous  proportion between  meat,  fat  and  bone. 
It appears  that other factors in animal  production  such  as  feeding  systems, 
and  management  may  still have  much  more  dominant  influences  on  meat  quality 
than  use  of anabolic  substances.  Much  more  detailed studies  are needed 
to increase  our  knowledge  of  these questions. 
As  regards  the  other aspects  of quality there  is  no  indication of  adverse 
effects on  meat  qualtiy.  A number  of  variations  have  been  recorded  but  in 
the  studies  made  none  of  the  changes  noted  have  been  demonstrated  to  be 
significant. 
12.  As  with  all  chemical  substances  in  widespread daily use  in  the  modern  world, 
there must  be  recognised  the possibility of  misuse  of authorised substances 
and  illegal  use  of  banned  substances. 
The  Commission  believes  that  the availability of  safe authorised substances 
will  discourage  the  temptation  of  the  illegal  use  of  banned  substances. 
However,  it will  always  be  necessary to establish an  efficient  Community 
system  of  control  and  monitoring  to  ensure  that  any  problems  may  be  traced 
to their source and  that appropriate  steps  are  taken  to prevent  potentially 
hazardous  products  from  reaching  the  consumer. - 6  -
13.  The  results  of  the  Commission•s  scientific work  were  submitted to the 
Consumers  Consultative  Committee  and  the  Veterinary Advisory  Committee, 
together  wit~ a  working  document  of a  draft  Legislative proposal.  On 
the basis oi  the sci,,ntific work  it was  proposed  that  the  three natural 
substances  be  authc  'sed subject to  conditions  but  that  the other  two 
substancef  should  r·0t  be  authorised for  the use  in the  Community. 
The  Consumers  Consultative  Committee  was  unanimously  opposed  to this 
Commission  orientation,  it does  not accept  the  validity of  the scientific 
reports  as  it considers  that biological effects are  insufficiently taken 
into account,  that  not  enough  consideration  had  been  given  to quality 
consequences  and  that  the problem  of  controls  was  not  solved. 
The  Veterinary Advisory  Committee  which  has  a  multiple  interest  repres-
entation including  the  Consumers  was  also  consulted.  In  general  there 
was  again opposition to the  Commission•s  orientation for  different  reasons. 
The  consumers•  representatives  maintained  their opposition on  quality 
grounds  and  in addition maintained  that  no  economic  benefits of  using 
the  substances  under  consideration had  been  demonstrated. 
Representatives  of  the  Industry,  co-operatives  and  the producers,  generally 
maintained that  a  ban  on  the  substances  •trenbolone•  and  •zeranol•  is pre-
mature  and  that  the  new  information being  made  available  should first  be 
studied.  Workers•  representatives  did  not  consider  that  sufficient  harmoni-
zation was  envisaged.  The  Veterinarians were  in general  agreement.  The 
representatives  of  Commerce  abstained  from  taking a  position but  emphasised 
the  need  for  controls.  All  interests  shared  the  view  that it is essential 
to establish appropriate  control  measures. 
The  conclusions  the  Commission  has  drawn  from  these  consultations are 
incorporated  in the present  proposal. 
14.  The  Commission  still considers  that proper  controls are essential. 
It  recognises  that  recently  in  February  the  Council  adopted  modifications 
to  the  "Third  Country"  veterinary  Directive and  to the  •Intra-Community 
Fresh  Meat"  Directive. 
. 
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With  the  latter the  obligation is  now  introduced  to make  sampling 
examination of animals  or  meat  for  residues  of  substances  having  a 
pharmacological  action and  of  the  conversion  products  thereof  and  for 
reference  methods  to be  laid  down  and  references  laboratories  designated 
~  by  the  Standing  Veterinary  Committee  prOc~dure after  the  Scientific Veterinary 
Committee  has  expressed an  opinion. 
Further  steps are,  however,  proposed.  It is  not  only  necessary  to  have  a 
Community  approval  of  the  substances  concerned.  It is  considered necessary 
that  individual  products  which  contain these  substances  are  also  subject  to 
approval  by  means  of  a  Community  procedure  using  the  relevant  criteria established 
in  the  Community  directives  on  veterina~y medicines.  In  this  way  the  further 
safeguards  concerning  dosage,  administration  and  period of delay  before  slaughter 
will  be  determined at  Community  level  for  ~ll products approved  to  figure  on  a 
Community  list.  Principles  of  conditions  of  use of any  approved  products  must 
be  respected,  including  restriction to  implantation  in  a  part of  the  animal 
which  is discarded at  slaughter,  obligation to  identify  the  animal  at  the  time 
of  slaughter and  respect  of  the  p~riod.of delay  laid down  for  each  approved  product. 
Provision must  be  made  for  Community  establishment  of  further details  of  the 
controls of  the  respect  of  the  conditions  of use  which  are  laid  down  at  the  time 
of  product  approval. 
For  the  banned  substances  other  controls are  provided at all  levels 
to  ensure  that  these  substances  are not  present either in factories  or 
pharmacie~on farms  or as  residues  in meat.  The  latter control  must  also 
be  applied  in  respect  of  any  approved  substances  as  an additional  check 
that  the  conditions  of  use  are being  respected and  that  residue  limits  .. are not 
exceeded. 
The  Commission  calls  upon  the  Council  to  take  an  urgent  decision on  this matter. ANNEX 
'REPORT  OF  THE  SCIEHTIFIC  VETERINARY  COJUIITTBE,  SCIENTIFIC  COJUIITTEB. 
FOR  ANIKAL  NUTRITION  AND  THB  SCIENTIFIC  COJUIITTBE  FOR  FOOD  ON 
··  THE.  BASIS  OF  THE  REPORT  OF  THB  SCIEHTIFIC  GROUP  ON · 
·ANABOLIC. AGENTS  IN.  ANII!AL~ PRODUCTION 
.  . I. 
': 
REPORT  OF  THE  SCIENTIFIC  VETERINARY  COMKITTEE,  SCIENTIFIC  COMMITTEE 
FOR  ANIIIAL  NUTRITION  AND  THE  SCIENTIFIC  COJDIITTEE  FOR  FOOD  ON 
THE  BASIS  OF  THE  REPORT  OF  THE  SCIENTIFIC  GROUP  0~ 
ANABOLIC  AGENTS  IN  ANIKAL  PRODUCTION 
I.  INTRODUCTION 
On  the  31  July 1981  the Council  adopted Directive 81/602/EEC(1)  concer-
ning  the prohibition of certain substances  having  a  hormonal  action  and 
of any  substance  having  a  thyrostatic action. 
By  Article 5  of that Directive  the  Council  decided  to  take  a  decision  as 
soon  as  possible on  the administering to  farm  animals  of oestradiol 170, 
testosterone,  progesterone,  trenbolone  and  zeranol,  for fattening  purpo-
ses.  It also noted the Commissions  intention  to  consult  the competent 
~-
Scientific Committees  on  the matter. 
The  Commission  asked  the Scientific Veterinary Committee,  the  Scie~tific 
Committee  for Animal  Nutrition  and  the Scientific Committee  for  Food  the 
question  : 
"Does  the use  for  fattening  purposes  in animals  of the following 
substances  :  oestradiol  - 17~,  testosterone,  progesterone,  trenbolone 
and  zeranol present  any  harmful effect to health." 
To  facilitate this work  a  specific Scientific Group  was  created in which 
representatives  of each  of the Scientific Committees  participated. 
This  document  contains  the report  adopted  by  the Scientific Group  as  a 
result of its final meeting of  22.9.1982.  This report was  made  availabl~ 
to the Scientific Committees  whose  opinion was  requested. 
The  Scientific Veterinary Committee  gave  its opinion at its meeting  on 
9.11.1982. 
The  Scientific Committee  on  Animal  Nutrition  gave  its opinion at its 33rd 
meeting  on  17.11.1982. 
The  Scientific Committee  for  Food  tave its opinion at its 39th meeting on 
4.02.1983. 
{1}  OJ  No  L  222  of 07.08.1981,  p.  32 - 2  -
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REPORT 
INTRODUCTION 
The  Council  Directive 81/602/EEC(l)  concerning  the use of certain 
substances  having  a  hormonal  action  and  of  any  substances having  a 
thyrostatic action stipulates  in Article 5  that the Council would  as 
soon  as  possible  take  a  decision  on  the use of  oestradiol-17~ , 
progesterone,  testosterone,  trenbolone  and  zeranol  for  the fattening 
of farm  animals.  For  this purpose  the Commission  was  required  to 
present  to  the Council,  a  report on  the collected experience and 
scientific developments  in  this field.  Consequently  a  Scientific 
Working  Group  was  set up  to advise  the Commission  of  the European 
Communities  on  whether  the use  of oestradiol-17}3 ,  testosterone, 
progesterone,  trenbolone  and  zeranol  as  anabolic  agents  in  animal 
production  was  a  risk to public health. 
The  Terms  of  Reference of  the Scientific Working  Group  were  as 
follows:  -
"Does  the  use  for fattening purposes  in animals  of  the following 
substances:  oestradiol-17)3,  testosterone,  progesterone,  trenbolone 
and  zeranol  present  any  harmful  effect to health?" 
In  framing  its advice,  the Scientific Working  Group  considered the 
2) 
guidelines  prepared by  the Scientific Committee  for  Food  •  the 
Scientific Committee  for Animal  Nutrition3)  and  the  Council  Direct-
ives  on  Veterinary Medicinal  Products  (81/851/EEC  and  81/852/EEC)4>. 
The  Working  Group  decided: 
a)  that  the most  suitable criteria for  assessing  the safety of  anabo-
lic agents  (growth  promoters)  were  those set out  in Part 2, 
Chapter I, Section A-D  of  the Annex  of Directive 81/852/EEC  of  28 
September 1981  on  the approximation  of laws  of  the Member  States 
relating to analytical,  pharmaco-toxicological  and clinical 
standards  and  protocols  in respect  of testing of veterinary medi-
cinal products. 
b)  that safety is related to  the conditions  of use of anabolic  agents. 
(1)  OJ  L 222  of 7.  8.1981,  p.  32 
(2)  Reports  of  the Scientific Committee  for  Food  (EUR  6892)  lOth Series 
(3)  Reports  of  the Scientific Committee  for Animal  Nutrition  (1980  EUR  6918} 
(4)  OJ  L 317  of 6.11.1981,  p.  1  and  16 - 4  -
The  Scientific Working  Group  gave  special consideration to a  number 
of general  points,  such  as  the need  to protect those  segments  of the 
population,  e.g.  prepubertal children,  which  were  most  likely to be 
affected from  the  toxicological point of view;  the distribution of 
residues  in edible tissues;  the conditions  of use  of anabolic  agents 
for  growth  promotion  and  improved feed  conversion  in  relation  to  the 
general  food  supply;  the need  to  avoid  illegal use;  and  the 
importance  of providing sensitive and  accurate monotoring  procedures 
on  which  to  base enforcement  of compliance with regulations. 
Enforcement  of proper conditions  of use  is essential for  safeguarding 
the  consumer. 
In  the opinion  of  the Scientific Group  the appropriate  conditions  of 
use  include 
a)  the site of application  should be  discardable, 
b)  the withholding  periods must  be  observed. 
Anabolic  sex hormones  like oestradiol-17fi ,  testosterone,  progestero-
ne,  trenbolone  and  zeranol  lead to  an  increased feed conversion  and 
hence protein deposition  in  farm  animals.  The  basic mechanisms  of 
action  on  the molecular level are not  completely understood.  However, 
there  is  increasing evidence that  the effects are mediated  through 
the  basic hormone-receptor  interactions.  The  food  of animals,  includ-
ing man,  normally  contains  natural  substances with  hormonal  activity. 
No  side effects  on  animal  health have  been  reported following  the 
recommended  use  of  these materials  in  growing  animals  other  than 
those related to their hormonal  effects  on  behavior  and  the reproduc-
tive system.  Behavioral  problems  may  occur  during  the first few  weeks 
following  treatment  but with  careful management  these problems  are 
not difficult to overcome.  The  use of anabolic agents  to promote 
growth  in  animals  intended for  breeding is contraindicated because  of 
their adverse effects on  the reproductive and endocrine  systems. 
2.  PRESENT  SITUATION 
Based  on  previous safety evaluations some  EEC  member  states have 
accepted the use  of trenbolone  and  zeranol  and  of  oestradiol-17~ • 
progesterone  and  testosterone. - 5  -
The  conditions  of use require  the drug  to be  implanted at  a  site (ear 
or  base  of ear)  which  is discarded at slaughter.  Withholding periods 
have  to  be  observed and  doses  applied per  animal  range  from  20-40  mg 
for  oestradiol-17p  and  zeranol. "'- 200  mg  for progesterone  and 
testosterone  and  140-300 mg  for  trenbolone  in  the form  of its acetate. 
Council Directive 81/602/EEC  of 31  July 1981  prohibits  the placing on 
the market  of stilbenes,  stilbene derivatives,  their salts and  esters 
and  thyrostatic  substances for administering  to  animals  of all 
species. 
The  Committee  did not  consider the  consequences  on  the quality of 
meat  of the use  of anabolic  substances. 
3.  ENDOGENEOUS  SEX  STEROIDS 
PROGESTERONE 
OESTRADIOL-17.8  ,  TESTOSTERONE  AND  • 
The  Scientific Working  Group  considered that evaluation of the 
safety-in-use of  oestradiol-17~ •  testosterone and  progesterone 
included consideration of  those derivatives which  readily yield the 
parent  compound  on  hydrolysis after absorption  from  the site of 
application. 
.... --.. 
Physiologically the steroidal sex hormones  oestradiol-17/3  and 
testosterone as  well  as  the gestagen  progesterone  control  the  proper 
function  of  the  sexual  physiology and  "anabolism"  in man  and  animals. 
The  sex  hormones  are  secreted by  the  gonads,  the adrenals,  and  the 
placenta,  the level of secretion  being  controlled by  a  complex  but 
well  established feedback mechanism.  Sex  steroids exert their hormo-
nal effects at  target tissues  by  binding to highly specific receptor 
proteins. 
Because  these  compounds  occur naturally they have  to be  considered as 
inevitable constituents of food  from  animal  origin.  Hormone  levels  in 
untreated animals  vary widely depending  on  species,  sex  and  physiolo-
gical state,  eg.  adult male cattle produce  40-50  mg  testosterone/24 
h,  cattle in late pregnancy several hundred milligrams  of 
~dstrogens/day.  Thus  the highest  tissue levels of  androgens  are found 
in  the mature male  animal  and  of oestrogens  in females  during  the 
later stages of  pregnancy.  Oestradiol-17)3,  testosterone  and 
progesterone  also  occur normally  in milk in  varying  amounts  depending 
on  the physiological state of the  animal.  In man  and  animals  endoge-
nous  sex  hormones  are rapidly metabolised predominantly  in  the - 6  -
liver to  compounds  exerting only little, if any,  biological activity. 
A  large percentage of these metabolites  is excreated directly in  the 
bile following  conjugation  (glucuronide,  sulphate).  However,  because 
of systemic circulation, metabolites  (both free  and  conjugated}  may 
be  found  in  the  tissues,  particularly in  the  kidney  and  liver. 
Because  there is a  natural endogenous  production  of  oestradiol-17~ , 
progesterone  and  testosterone  in all farm  animals,  any  residues  of 
these steroids  are qualitatively indistinguishable from  those  derived 
from  the  use  of  these same  steroids  as  anabolic  agents  administered 
to animals  during life.  Under  appropriate conditions  the  treatment of 
animals  with  exogenous  natural  steroids results  in  residues  in  edible 
tissues which  are orders  of magnitude  lower  than  those  that  can  occur 
naturally  in mature males,  females  and  pregnant females.  Therefore  in 
practice no  quantitative differences  have  been  observed between 
treated and  untreated animals  when  the  recommended  conditions  of use 
were  observed.  Levels  in  treated and  untreated calves are of the . 
order  of 0.1 ug  testosterone/kg and  0.03  ~g natural  oestrogens/kg 
edible tissues. 
No  problems  arise concerning  contamination  of the  environment  as  a 
result of the  administration of endogenous  hormones,  given  the natu-
ral background  of  these substances  and  their biodegradability. 
Levels  and  production rates of endogenous  natural  sex  hormones  vary 
in humans  with  age,  state of sexual maturity, menstrual  cycle  and 
pregnancy.  Daily production of oestrogens  in  infants  ranges  from 
1-40 ug,  in man  from  40-130 ~g.  in women  during  reproductive life 
from  50-450 ~g.  in menopausal  women  from  5-40  ~g. Daily production of 
testosterone  in  infants  is about 100  ~g.  in man  4-10 mg,  and  in women 
120-300 .g. 
In relation to  the  endogenous  sex steroid production  in  the  human, 
the actual  amount  of sex  steroids  consumed  with  food  of  animal  origin 
is  toxicologically negligible as  these steroidal residues  do  not 
reach  effective concentrations at  the relevant hormone  receptor sites 
in  target  tissues.  Koreover,  the low oral bioavailability  (less  than 
15  ~)  of  these steroids and  the existing tissue barriers  in  the liver 
and  placenta effectively prevent  any  adverse  toxicological effects 
from  the  ingestion of  the minute  residues  of natural  sex steroids 
which  may  be  present  in all edible tissues  of  animals  treated with . , 
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anabolic  hormones.  Thus  no  questions  of safety arise in relation  to 
the proper use  of  oestradiol-17~ ,  progesterone and  testosterone in 
an  appropriate form  of preparation. 
4.  EXOGENOUS  ANABOLIC  AGENTS 
4.1.  Trenbolone  (17-~  hydroxy  trenbolone) 
Trenbolone  is  a  synthetic steroid with  androgenic  activity similar to 
testosterone  but with greater anabolic  activity.  It has  several 
structural features  similar to testosterone but unlike  testosterone, 
it has  three  conjugated double  bonds,  and  is chemically less stable. 
The  material  normally  in  commerce  is trenbolone acetate. 
Metabolism  and  Residues 
The  metabolism of trenbolone acetate has  been  studied in  the rat, 
calf,  heifer,  cow  and  steer.  Trenbolone  acetate is rapidly hydrolysed 
to  trenbolone,  and  both  trenbolone  and  its metabolites  are rapidly 
excreted as  the  glucuronides and  sulphates. mostly  in  the bile.  The 
predominant metabolites  identified in  the extractable fractions  of 
bile in  the rat are trenbolone  and  a  16-0H  and  a  17-keto metabolite; 
while  in  cattle it is mainly  17~-hydroxy trenbo1one with  small 
amounts  of  trenbolone  and  other metabolites.  Many  of  the minor 
metabolites  have  been  identified in  both  species.  The  parent  compound 
and  its metabolites have  low oral activity. 
Following  the recommended  use of trenbolone acetate  in cattle and  the 
application  of  various methods  of  assay  {radioimmunoassay.  thin-layer 
and  high  performance liguid chromatography)  the main  metabolite found 
in muscle  has  been  shown  to  be  trenbolone  (<0.5  ppb  muscle)  and  in 
liver and  kidney  a  conjugated form  at 17  hydroxy  trenbolone  ((3  ppb). 
17~-hydroxy trenbolone  has  a  biological activity at least 10  times 
less  than  17~ hydroxy  trenbo1one. 
Similarly following  subcutaneous  implantation  of cattle with  trenbo-
lone radiolabelled with  tritium.  total residues,  expressed as 
trenbolone equivalents,  were  a  few  parts  per billion  (10-
9
)  in 
muscle  and  approximately 10  times  higher  in liver and  kidney  (5-35 
ppb).  5-10 ~of the total residues labelled with  tritium are 
extractable from meat,  liver or kidney,  and  have  been  identified as 
similar to those found  in bile.  The  identity of the remaining - 8  -
unextractable residues,  labelled with  tritium,  which  are most  likely 
irreversible bound,  is not  known  but  some  tritium is found  in  the 
body  water.  The  bioavailability of these unextractable residues  in 
liver,  kidney  and muscle,  following  ingestion  in rat feeding  studies 
was  found  to  be <  10  1.. 
Toxicity studies.  Acute  toxicity studies  in several  species  showed 
trenbolone  to  be  of low oral toxicity. 
In  subchronic  toxicity studies  trenbolone acetate was  administered 
for  8 weeks  in  the diet of mice  without  any  significant changes  apart 
from  those related to hormonal  activity,  which  were still present  at 
25  mg/kg  diet,  the lowest level  tested.  Similar subchronic  studies  in 
normal  male  and  female  rats and  in castrated male  rats,  extending 
from  10  days  to  3 months,  showed  increased size of liver,  kidney  and 
spleen at high  doses  and  the expected hormonal  changes  down  to dose 
levels of  50  ~g/kg bodyweight.  A 14  weeks  oral feeding  study  in  pigs 
produced  increased liver weight  and liver cell size  in  females  at 
levels of 2  and  20  mg/kg  diet. At  the lowest dose level of 100  »g 
trenbolone  acetate/kg diet tested there was  no  clear absence  of a 
lack of a  hormonal  effect. 
A life-span feeding  study in  the mouse  (dose range  0.5-100 mg/kg 
diet)  extended over  about 100  weeks.  There was  some  increase  in 
kidney weight  at  the highest dose  levels  in females  sacrificed at 13 
weeks,  an  effect typical of  androgenic activity. At  terminal sacrifi-
ce  no  organ weights were  recorded,  but  there was  an  increased incide-
nce  of liver nodular hyperplasia and  tumours  in males  of all dose 
groups  which  reached significance at the two  highest  dose levels and 
for  females  at the highest dose  level tested.  The  control mice  also 
had  a  high  incidence of liver tumours. 
Female  rats were  administered with  trenbolone  acetate during 
pregnancy  and  the  pups  used  in  a  112  week  feeding  study,  using  doses 
of 0.5-50 mg/kg  diet.  A number  of mild  toxic  changes  were  seen  at the 
highest  dose  level.  A clear cut no-effect level for hormonal  activity 
could not  be  determined.  However,  the data indicated that  (since  the 
lowest  dose  group  showed  no  significant changes  in all parameters 
examined  compared  to controls)  a  concentration of 0.5  ppm  in  the diet 
(25 ,..rtg/kg  B.W.)  is the  probable  "no-hormonal  effect level" for  the 
rat.  This  result reguires confirmation.  An  increased  (though  not 
statistically significant)  incidence of pancreatic islet cell tumours - 9  -
was  seen  at  the highest dose level  (50  mg/kg  diet).  A one-generation 
reproduction  study  in rats.  using  0.5-16 mg/kg  diet  in males  and 
0.5-50 mg/kg  diet in  females  showed  a  dose  related effect on 
pregnancy rate and litter parameters.  No  teratogenic effect was  seen 
in  two  feeding  studies  in rats.  A relay toxicity study has  shown  that 
meat  from  cattle treated at doses  10-25  times  greater  than  the  normal 
doses  for  17~ oestradiol  and  trenbolone  acetate  showed  no  effects in 
rats. 
Because  of  the  irreversible binding of  some  residues  to macromolecu-
les.  which  may  indicate a  genotoxic  potential,  special  attention was 
given  to mutagenicity tests with  trenbolone. 
Genotoxicity was  examined  by  mutagenicity tests and  by  the capacity 
for  DNA  binding.  Neitherj3-Trenbolone  no~  -Trenbolone  showed  any 
mutagenic  activity in prokaryotic  systems nor  in  any  in  vivo test for 
bone  marrow  and  germ  cell cytogenetics.  Clastogenic  activity in vitro 
against human  lumphocytes  in culture were  negative  but  tests against 
cells  (L  5178  mouse  lymphoma)  were  slightly positive.  but  to  the  same 
degree  shown  by  testosterone and  oestradiol.  Concerning  DNA  binding 
in  vivo  in rats covalent  binding  indices were  very  low  and  equivalent 
for  trenbolone  and  testosterone and  less  than for oestradiol.  The 
data available  to  the group do  not  indicate any  genotoxic activity. 
The  question  of  binding  to macromolecules  other  than  DNA  is a  general 
problem which  the  group consider worthy  of further  study. 
The  findings  of  the  carcinogenicity studies  in rodents  are difficult 
to interpret because  of  the interference by  the  hormonal  activity of 
the  dose  levels  employed  and  the  comparatively  high  incidence of 
liver tumours  in  the controls used  in  the mouse  study.  The  results of 
the mutagenicity tests do  not  indicate genotoxic  activity.  Hence  the 
increased  tumour  incidence observed at high  dose levels is probably 
due  to epigenetic mechanisms  related to the modulating effect of the 
hormonal  activity on  the mechanism  of  tumour  production. 
The  present  information  on  the  average daily consumption  of  m~~cle 
tissues  and  offals within  the  EEC  suggest  that  the  consumer  would 
probably  be  exposed to similar amounts  of l)<and  17~-hydroxy trenbo-
lone  through  his  food.  Therefore more  toxicological  information - 10  -
particularly the determination of  the  no  hormone  effect level of 
17~-hydroxy trenbolone  is desirable.  In  summary  for  trenbolone, 
establishment  of  the no  hormonal  effect level of  17-~ and  17-~ 
trenbolone is reguired.  Clarification is reguired of carcinogenicity 
data of  17~ trenbolone particularly from  the  chronic  toxicity study 
by  taking  into account  the mutagenicity studies  already  completed. 
4.2.  Zeranol 
This  substance  is structurally not  a  steroid and  does  not  itself 
occur  in nature  although  the parent substance zearalenonde  is a 
natural  substance elaborated by  Gibberella Zea.  It has  oestrogenic 
and  anabolic activity. 
Metabolism 
The  metabolism has  been  studied in  a  number  of  species  including 
cattle and  sheep.  Most  of the orally administered  substance is 
absorbed and eliminated in  the faeces  and  urine.  The  proportions  of 
urinary and  faecal  elimination is species dependent. 
Zeranol  is excreted both  as  free  and  conjugated substance  and  as  free 
and  conjugated zeralanone.  The  same  metabolites  appear  in  the bile. 
Most  of orally administered zeranol  has  practically disappeared from 
the  tissues within  24  hours  except for  the liver and  kidney,  however, 
no  thorough  identification of the possible metabolites  has  been  made 
in  the relevant species. 
The  oestrogenic properties were  studied in many  species using 
comparatively high  doses  but a  no-hormonal  effect level  has  not  been 
determined,  activity still being detectable at levels of 
30-50 •&!animal/day  in rats  and mice.  However,  in vitro assays  point 
to zeranol  having  about  20  ~of the oestrogenic activity of 
oestradiol. 
Toxicity 
Zeranol  has  a  low  acute oral  toxicity in most  species.  Subchronic 
feeding  studies for 13  weeks  in  the rat showed  hepatotoxicity in  both 
sexes  and  none  of  the doses was  free  from  hormonal  activity  (lowest 
dose  tested 0.25 mg/kg  bodyweigbt).  Feeding  studies  in  dogs  ranging 
from  6-104  weeks  and  over  a  wide  range of doses  showed  some  haemato-
logical effects at high  dose  levels  andevidence of gross  hormonal - 11  -
effects at all levels  tested.  A no-hormonal  effect level was  not 
determined. 
A life span  feeding study in rats over  2  years  at dose  levels  from 
0.8-20 mg/kg  bodyweight/day showed  hormonal  effects  in males  and 
females  at all dose  levels.  Some  haematological  effects at the 
highest dose  levels  as well  as  microscopically detected hapatotoxici-
ty at all levels were  noted.  Mo  carcinogenic effects were  seen. 
A seven  year  study in  female  beagles  showed  variable toxic effects at 
the  high  dose  level on  the haemopoietic  system with  increased weights 
of liver.  kidney  and  adrenals  at all levels  but also significant 
effects due  to hormonal  activities on  all reproductive  organs  at both 
dose  levels.  Female  beagles were  hypterectomised.  Although not 
specially designed for  this purpose.  no  carcinogenic effects were 
seen. 
A ten  year feeding  study  in female  rhesus monkeys  using  a  dose  range 
of 15  and  75  mg/kg  bodyweight  showed  some  haematological  changes  at 
the highest  dose level  and  alteration in hepatic  function  at both 
dose levels  tested with  increased liver weight at termination.  Both 
dose  levels  showed  significant hormonal  effects on  the reproductive 
system.  hence  a  no-hormonal  effect level was  not determined.  Although 
not  specially designed for  this purpose.  no  evidence of  carcinogeni-
city was  found. 
A three-generation reproduction  study  in rats  combined  with  a 
teratology  study  showed  no  adverse effects at all levels up  to 
200  ~g/kg diet.  Another  teratology study  in rats  showed  inhibition of 
implantation  at  the  lowest  dose  tested  (1  mg/animal/day  during 1  to  4 
of gestation).  A similar study  in mice  gave  no  effects  on  pregnancy 
and litter parameters at doses  below 100  pg/kg  bodyweight without 
showing  any  teratogenic effects. 
Mutagenicity was  studied  in  prokaryotic  systems  but  the  toxicity of 
zeranol  for  the  indicator organism made  the  study difficult to 
interpret.  Low  level exposures  in  these  systems  produced  no  mutagenic 
effects. 
In  summary.  although  a  large number  of studies have  been  performed 
with  zeranol.  there  are  insufficient data  on  the nature of the 
metabolites.  on  the guantity and  nature of  the residues  in the 
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edible tissues of  anima~s and  on  mutagenicity to interpret the 
available information  in  terms  of the safety or otherwise of zeranol. 
A sufficiently sensitive method  for determining unlabelled zeranol  in 
edible tissues  is not available,  although  a  satisfactory method  is 
available for urine of cattle and  sheep.  There  is not sufficient 
information  about  the chemical  impurities  of  the commercial  product. 
None  of  the experiments  permit  the establishment of a  no-hormonal 
effect level necessary for  the interpretation of the toxicological 
significance of any  residues  found  in edible tissues of treated 
animals. 
5.  Conclusions  and  recommendations 
5 .1. 
The  Scientific Working  Group  is of the opinion  that  the use of 
oestradiol-17~ ,  testosterone and  progesterone and  those derivatives 
which  readily yield the parent compound  on  hydrolysis after 
absorption  from  the site of application,  would  not  present  any 
harmful  effects  to  the health of the consumer  when  used under the 
appropriate conditions  as  growth  promoters  in farm  animals. 
5.2. 
Evaluation  of  the data on  "trenbolone"  and  "zeranol"  revealed that 
some  data on  the hormonal  non-effect-level  and  the  toxicology of 
these compounds  and  their metabolites  are still missing. 
5.3. 
The  Scientific Working  Group  considers it necessary  that additional 
information be  provided before a  final conclusion  can  be  given  on 
trenbolone  and  zeranol. 
5.4. 
Proper programmes  to control and  monitor the use of anabolic  agents 
are essential. 
5.5. 
It is necessary  to  continue scientific investigations  on  the releva-
nce  of the present use  of the  "no-hormone  effect"  level related to 
the harmful effects of anabolic  agents. '  ' 
.. 
' 
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R.  VIVIANI 
"The  ColiiDittee  unanimously  agreed that it fully  supports  the 
conclusions  and  recommendations  of the report  of the Commission 
Scientific Group. 
However,  the Co111nittee  attracted the attention of  the Co111nission  to 
the urgent  need for further discussion  and  action  to establish  : · 
(a)  the conditions of use, 
(b)  methods  of analysis, 
(c)  monitoring programmes, 
as regards  these substances." 
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2.  OPINION 
"The  Conanittee  has  examined  the report by  the Conanission's  scientific 
working  group  on  anabolic agents  used  in livestock production  and  has 
approved its conclusions  and  recommendations. 
The  Committee.  however.  wishes  to draw  the Commission's  attention to 
the need  to lay down  certain essential provisions.  in  particular as 
regards  the following  : 
a)  Instructions for use 
1.  Specification of  the doses.  the  type  of pharmaceutical 
preparation.  the number  and  frequency  of administrations. 
2.  Association  of anabolic  agents. 
3.  Localization of  implant  and  ablation  of zone  treated. 
4.  Withdrawal  period before slaughter. 
5.  Identification of  animals  treated.  with  indication of the 
period of  treatment. 
b)  Surveillance progranane  and  analysis methods 
1.  Control  of production  and  trade  in anabolic  agents. 
2.  Veterinary control of authorized uses. 
3.  Keans  and methods  of control." - 26  -
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2.  The  Committee  gave  its opinion at its meeting of  the  4  February 1983. 
Terms  of Reference 
To  give an  opinion  on  whether  the use for fattening  purposes  in 
animals  of  the following  substances  :  oestradiol  -17P,  testosterone, 
progeste~one,  trenbolone and  zeranol  present any  harmful effect to 
health. 
Back.ground 
On  the 31  July 1981  the Council  adopted Djrective 81/602/EEC(l) 
concerning  the prohibition of certain substances  having  a  hormonal 
action  and  of any  substance having  a  thyrostatic action. 
By  Article 5  of that Directive the Council  decided  to  take  a  decision 
as  soon  as  possible on  the administering  to farm  animals  of 
oestradiol  -17fo,  testosterone,  progesterone,  trenbolone  and zeranol, 
for fattening  purposes.  It also noted  the  Commission's  intention  to 
consult  the  competent Scientific Committees  on  the matter. 
The  Commission  asked  the Scientific Veterinary Committee,  the 
Scientific Committee  for Animal  Nutrition  and  the Scientific 
Committee  for  Food  the  same  question,  recognizing  that the  three 
committees  would  lay emphasis  in  their separate reports  on  the 
aspects  of  the question which  fell within  their terms  of reference. 
The  three Committees  established a  joint working  group  composed  of 
members  of  the  committees  with special knowledge  of  the subject. 
A number  of eminent  specialists in  the field joined the working  group 
which  met  several  times under  the auspices  of the Commission  Services 
as  a  "scientific working  group  on  anabolic  agents  in  animal 
production". 
{1)  OJ  No  L 222  of 07.08.1981,  p.  32 .·.-. 
r:' 
' . 
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The  Scientific  Co:mmi ttee  ·.for Food,  together with  the Scientific 
Committee  for Animal  Nutrition  and  Scientific Veterinary Committee, 
was  requested to consider the report of  the Scientific Working  Group 
and  to comment  on  its conclusions  and  recommendations  during  the 
Committee's  own  review. 
The  committee  has  been  informed  that  the Commission  intends  to make 
public  the report of  the Scientific Working  Group.  The  Committee 
also notes  that  the Scientific Veterinary Committee  and  the 
Scientific Committee  for Animal  Nutrition have  both  already made 
recommendations  to the Commission  on  the proper use  of  these  anabolic 
agents. 
Current  Review 
The  Committee  is  impressed  by  the  thoroughness  with  which  the report 
of  the joint working  group has  been  prepared.  There  appears  no 
reason  in  the present report  to reherse all the reasoning  included 
therein,  particularly in  view of its imminent  publication. 
The  conclusions  of the Scientific Working  Group  were  as  follows 
1.  The  Scientific Working  Group  is of the opinion  that  the  use  of 
oestradiol  -17~,  testosterone and  progesterone,  and  those deriva-
tives which  readily yield the parent  compound  on  hydrolysis after 
absorption  from  the site of application,  would  not  present  any 
harmful  effects to  the health  of the consumer  when  used under  the 
appropriate conditions  as  growth  promoters  in  farm  animals. 
2.  Evaluation  of  the  data on  "trenbolone"  and  "zeranol"  revealed  that 
some  data on  the  hormonal  no-effect level  and  the  toxicology of 
these  compounds  and  their metabolites  are still missing. 
3.  The  Scientific Working  Group  considers it necessary that additio-
nal  information  be  provided before  a  final conclusion  can  be  given 
on  trenbolone  and  zeranol. 
4.  Proper programmes  to  control  and  monitor  the use  of anabolic 
agents  are essential. 
5.  It is necessary  to  continue scientific investigations  on  the 
relevance of the present use  of the  "no-hormone  effect"  level when 
related to the harmful  effects of  anabolic agents. - 28  -
Conclusions  and  Recommen~ati~ns 
In general,  the Scientific Coaaittee for Food  agrees with  the  ; 
conclusions  and  recommendations  of the Scientific Working  Group.  It 
also wishes  to put forward  the following  comments  for  consideration 
by  the Commission 
i)  In relation to Recommendation  2 it would  be  of interest to 
generate data on  the  threshold values  for  the  toxic and  ho~o­
nal activities of trenbolone and  zeranol. 
ii)  The  Committee  endorses  the Recommendation  4  on  the  importance 
of  implementing  programmes  for control  and monitoring of anabo-
lic agents.  It emphasizes  that proposals  should be  made  by  the 
Commission  for  implementation.  In connection with  this aim it 
would  be  necessary to encourage  the development  and  standardi-
sation of appropriate analytical methods. 
iii}  The  Committee  recognises that  the possible misuse of naturally 
occurring hormones  or their derivatives,  which  easily yield the 
original  ho~one, may  be  difficult to detect analytically. 
Info~ation is therefore needed  on  the levels of naturally 
occurring  bo~ones likely to engender  a  health hazard.  It is 
an  important public health consideration to prevent  the illegal 
use of banned  products and  the misuse of authorised products  by 
efficient monitoring and  proper controls. Proposal for a 
COUNCIL  DIRECTIVE 
amending  Directive 81/602/EEC  concerning  the prohibition of certain 
substances having a  hormonal  action and  of any substances 
having a  thyrostatic action Proposal for a 
COUNCIL  DIRECTIVE 
amending  Directive 81/602/EEC  concerning  the  prohibition of certain 
substances having a  hormonal  action and  of any substances 
having a  thyrostatic action 
THE  COUNCIL  OF  THE  EUROPEAN  COMMUNITIES, 
Having  regard  to  the Treaty establishing the  European  Economic  Communit~ and 
in particular Article 43  thereof, 
·H~ving regard  to  Council  Directive 81/602/EEC  of  31  July  1981  concerning the  prohi-
bition of  certain  su~'~ances having  a  hormonal  action  and  of  any  substances  having 
a  thyrostatic action  ,  and  in particular Articles  5  and  7  thereof, 
Having  regard  to  Council  Directive  64/433/EECc~! 26  June  1964  on  health  problems 
affectingd9tra-Community trade  in  fresh  meat  ,  as  last  amended  by  Directive 
83/90/EEC  ,  and  in particular Article 4(2)  thereof, 
Having  regard  to  the proposal  from  the  Commission, 
Having  regard  to  the opinion of the European Parliament, 
Having  regard  to  the  opinion of  the Economic  and  Social Committee, 
Whereas  the adoption of Community  provisions  concerning the  absorption  by  farm 
animals  of substances having a  hormonal  action or thyrostatic action have  the 
object,  in the interest of  consumers,  of  protecting  human  health  and  of  removing 
barriers  to  intra-Community  trade of animals,  meat  and  meat  products  resulting 
from  differences between  the health requirements  of Member  States; 
Whereas it is,  therefore,  necessary to  supplement  the  provisions  already  laid 
down  on  the matter by  the  aforementioned Directive  64/433/EEC  and  Council 
Directive 71/118/EEC  of 15  February 1971,  concerning health problems  of trade 
in fresh  poultrymeat(4),  as last  amended  by  Directive  (5) 
and  by  the  aforementioned  Directive 81/602/EEC; 
(1)  OJ  No  1222,  ·7 •.  8.1981,  p  32 
(2)  OJ  No  121,  29.  7-1964,  p  2012/64 
(3)  OJ  No  1  59,  5.  3-1983,  p  10 
(4)  OJ  No  L  55,  8.  3-1971,  p  23 
( 5)  OJ  No  1  .19  t  p - 2  -
Whereas,.  in accordance  with  Article 5 of  Directive 81 /&12./EEC,  it is necessary to take a 
decision as  soon as possible on  the administering to farm  animals  of 
Oestradiol 17p,  Progesterone,  Testosterone,  Trenbolone and  Zeranol for 
fattening purposes; 
Whereas  it is important  to  authorise only substances which  have  a  favourable 
effect on  farm animal  production and  whose  administration will neither present 
harmful effects on  human  health nor harm  the  consumer  by  altering the 
characteristics of meat; 
Whereas  the  Scientific Veterinary Committee,  the  Scie~tific Committee  for  Animal 
Nutrition and  the Scientific Committee·  for  Food  have  studied this problem  on  the 
basis of  a  report of a  Commission  scientific group  on  anabolic  agents  in animal 
prcxiJction,  ard whereas  the  Commission  has  declared its intention to  continue  to  consult 
these  Committees  and  the  numerous  interested parties  in particular the  consumers 
on  these questions.  · 
Whereas  it appears  that some  data necessary on  the  toxicology of  Trenbolone 
and  Zeranol  and  their metabolites are still lacking;  whereas,  in 
consequence,  their use  for fattening purposes  must  in the present  citcumstances 
be  prohibited: 
Whereas,  on  scientific grounds,  it appears  that  the use  of Oestradiol 17fl, 
Testosterone and  Progesterone and  those  derivatives which  readily yield  the 
parent compound  on  hydrolysis after absorption from  the site of application 
would  not  present  any  harmful  effects  to  the health of  the  consumer  nor harm 
the  consumer  by  altering the characteristics of meat  when  used  under  the 
appropriate  conditions as  growth  promoters in farm  animals;  whereas,  in 
consequence,  Member  States may  authorise their use  for fattening purposes; 
Whereas  approval  of products  containing authorised  substances must  comply  with 
the  relevant principles and  criteria set out  in Council Directive 81/851/EEC 
of 28  September 1981  on  the approximation of the  laws  of  the Member  States 
relating to veterinary medicinal  products(6),  and  Council  Directive 
81/852/EEC  OF  28  September 1981  on  the approximation of the  laws  of Member 
States relating to analytical,  pharmaco-toxicological and  clinical standards 
and  protocols in respect of the  testing of veterinary medicinal  products(7); 
(6)  OJ  No  L317, 
(7)  OJ  No  L317  , 
•6.11.1981,  p  1 
6.11.1981,  p  16 - 3  -
whereas additional requirements as  regards  carrier substances,  conditions of 
use  and  withdrawal  periods must  also  be  complied with;  whereas  a  Community 
procedure within  th~ Standing Veterinary Committee,  set up  by  Council  Decision 
of 15  October 1968
18
),  should  be  used  to establish a  list of products  which 
may  be  approved  a· Ld  the  cm·,Ji tiona  of their use,  as well as  to modify  the list 
of authorised  sul stances  · ··  the light of progress in scientific and  technical 
knowledge; 
Whereas  Member  States L·ay  choose not  to allow in their terri  tory the marketing 
and  administration to farm  animals,  for fattening purposes,  of substances and 
products which  may  be  authorised under the present Community  rules,  but  must 
not  raise any obstacle for human  health reasons  to  the  importation of animals, 
meat  and  meat  products  from  other Member  States where  such substances  and 
products have  been authorise1 in accordance with Community  rules; 
Whereas  it is  su~table to prescribe,  in accordance  with Article 7  of Directive 
81/602/EEC  and  Article 4<2>  uf Directive 64/433/EEC,  the measures 
necessary for  the control of farm  animals,  of meat  and  meat  products in 
relation to  the use of substances having a  hormonal action or thyrostatic 
action,  as well as  tolerances for these substances  and  the  frequency  of 
sampling;  and  that  these measures must  also facilitate the  cooperation between 
Member  States in the application of these controls and,  where  necessary, 
provide for the adoption,  in accordance with procedure of the Standing 
Veterinary Committee,  of measures  necessary  to  ensure  the  coordination and 
uniform application of these  controls; 
HAS  ADOPTED  THIS  DIRECTIVE: 
Article 1 
Directive 81/602/EEC  is hereby  amended  as  follows: 
(8)  OJ  No  1255 ~  18.10.1968,  p  23 ) 
' 
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1.  Article 5  is  replaced by  the  following: 
"Article 5 
1.  By  to~ay of derogatioo  fran Article 2,  MeTtler  States may  authorise the 
administering to farm  animals,  for  fattening purposes,  of 
Oestradiol  17t3,  Testosterone and  Progesterone and  those derivatives 
which  readily yield the  parenLcompound  on  hydrolysis after absorption 
from  the site of application. 
2.  Member  States shall  ensure  that  the  aforementioned  substances  are: 
- only administered  to farm  animals  by  implantation which  is  located 
in a  part of  the  animal  which  must  be  discarded at slaughter 
- only  administered to animals  which  are  identified at  the~time of 
implantation and  that these animals  are not slaughtered before  the 
expiry of  the  delay period  laid down  in application of  subparagraph  3a) 
- administered by  a  veterinarian. 
3.  a),  Before  1  April  1986  in accordance  with  the procedure  laid down  in 
Article 16  and  following  the  relevant  principles and  criteria of 
Directives 81/851/EEC  and  81/852/EEC  there shall  be  established: 
-a list of  products  containing as  active substances  the  substances 
referred to  in paragraph  1  which  may  be  approved  for marketipg 
and  use  in the  Community 
- the  conditions  of  use  of products contained  in  the  abovementioned 
list in application of paragraph  2,  in particular the delay period 
necessary and  detailed provisions  concerning  the  control  of  these 
conditions  of  use 
- the  means  of  identification of animals. 
b)  Member  States shall ensure  that  the products mentioned  under 
subparagraph  a>  are  subject .to  the  rules of Articles 24  to  SO  of 
Directive 81/851/EEC  except  for  those  rules which  relate 
to the national authorisation for marketing. - 5 -
4.  In order to take· account  of  sci~ntific and  technical  progr~ss, the  list  of 
substances  referred  to  in paragraph  1  which  may  be  administered to 
animals  for  fattening  purposes,  ~ay be  completed  or amended  in accordance 
with  the procedure  laid down  in Article 16. 
Any  substance which  may  be  authorised: 
- must  have  a  favourable  effect on  farm  animal  production 
- must  not  endanger  human  or animal  health  nor  harm  the  consumer  by 
a l te  ring  the  cha ra cte ri sti  cs  of  farm  animal  products 
-must. comply  with  the  relevant  principles and  criteria of Directives 
81/851/EEC  and  85/852/EEC. 
5.  However,  any  decision  concerning the possible  inclusion of  Trenbolone  or 
Zeranol on-the  list shall  be  made  by  the  Council- acting  by  a  qualified 
majority on  a  proposal  from  the  Commission,  and  in  conformity wi·th  the  other 
conditions  laid  down  in  paragraph 4." 
2.  Article 7  is  replaced  by  the  following  Articles: 
"Article 7 
Without  prejudice  to  the  provisions of Directive 64/433/EEC,  Member  Statesshall 
ensure  that  checks  on  compliance  with  the  prohitions as  laid dow1  in Articles 2 and 
3,  checks  on  farm  animals,  the meat  of such animals,  the meat  products 
obtained  therefrom for  the  presence of residues of hormonal  substances 
referred  to in Article  2(a)  and  checks  on  c:orrpl:iance  with  the corditions of  use  of 
products  provided  for  in Article  5  are  carried out  in their territory  in 
accordance  with  the provisions  of this  Directive. 
Article 8 
Member  States shall ensure  that on-the-spot  random  checks  for  the  presence of pro-
hibited  substances  as  referred  to in Articles 2  and  3  are made  officially at 
the  levels of manufacturing,  handling,  storage,  transport,  distribution and 
sale. 
Article 9 
1.  Member  States shall ensure  that on-the-spot  random  checks are made 
officially for  the presence of prohibited substances  as  referred  to  in 
Articles 2  and  3  at agriculture holdings where  animals are  reared,  held  or 
fattened  for slaughter. 
2.  The  checks  shall include  taking  random  samples  from  animals  for  examination 
for  the  presence  of residues. 
I  • - 6 -
Article 10 
1.  Member  States shall ensure  that  random  checks are  taken officially from 
animals  and  meat,  including meat  destined  for  the  production of  meat 
products,  at  the  slaughterhouse of production for examination for  the 
presence  of  residues  of substances mentioned  in Article 2(a). 
2.  In particular,  random  samples shall be  taken of animals  and  meat  from 
holdings  submitting regularly calves and  fattened  bovine animals  for 
slaughter. 
Article 11 
1.  The  samples  referred to in Article 9  (2)  and  Article 10  shall be 
taken officially and  examined  by  an authorised laboratory for the presence 
of residues. 
2.  The  examination for residues  referred to in paragraph 1  must  be  carried  out 
in accordance with proven methods  which  are scientifically recognised,  in 
particular those  laid down  by  Community  provisions. 
It must  be  possible  to  assess  the  examination for residues using  the 
reference methods  established .in  accordance with Article 4(1>(b)  of  Directive 
64/433/EEC. 
3.  All positive findings shall be  confirmed  by  an official laboratory using 
the  reference method  referred to above in paragraph 2. 
Article 12 
1.  Where  examination  as  referred to  in Article 11(3)  has  confirmed  the 
presence  of prohibited  substances  or of residues  exceeding  the  maximum 
natural physiological  levels of authorised substances,  the  competent 
authorities shall be  informed without  delay of: 
a)  all information needed  to identify the origin of the animals 
b)  the  result of  the examination. 
2.  The  competent authorities shall thereupon ensure  that: 
a)  an investigation is made  at  the  farm  of origin to  determine  the  reason 
for  the presence of residues 
b)  an  investigation of  the  source or  sources  of  the  substanc~concerned is 
made  as  necessary at  the  levels of. distribution,  sale,  tran~por~,: 
handling,  storage and  manufacture. - 7 -
3.  The  competent  authorities shall also ensure  that: 
a)  the  herd  or animals at the  farm  of origin and  herds  which,  as  a  result 
of  the  investigations  referred  to in paragraph 2  may  be  assumed  to 
contain the  residue  in question,  are provided  with official marking  and 
subject  to  ippropriate  examinations 
b)  if the  exaaination  :eveals the presence  of prohibited  substance~,  the 
animals  shall be  ccnfiscated or destroyed 
c) if the  ~Laminaticn reveals  the  presence of  residues  of  authorised  substances 
above  the  limits mentioned  in paragraph 1,  the slaughter of the  animals 
concerned  for human  consumption  shall  be  prohibited until it can  be  ensured 
that  the  amount  of residue  no  longer exceeds  the permitted levels.  This 
period  may  in no  case  be  shorter than the  delay period fixed for  the 
substance in application of Article 5 (3)(a),  However,  where it 
is ascertained that the  conditions of use  laid down  have  not  been  com-
plied with;  the  animals  concerned  shall be  confiscated or destroyed 
d)  during  the  period of examination,  the animals must  not be  disposed of to other 
parties. 
4.  B,y  way  of derogation from  paragraph  3Cc>,  animals  whose  slaughter is 
prohibited  may  be  slaughtered  before  the  end  of the prohibition period if 
the  competent  authority  is informed at least  one  week  before  the  proposed 
slaughter date,  stating the  place of slaughter.  The  officially marked 
animals  must  be  accompanied  to  the place  of slaughter by  an official 
veterinary certificate containing the  information required  under 
paragraph  1 (a). 
The  carcase of each animal whose  slaughter is notified pursuant  to  the  above 
su~aragraph shall be  officially examined  for  the  residue  concerned  and 
shall be  detained until  the  result of the  examination is known. 
Article  1':5 
Where  the  checks  and  investigations referred  to in Articles  8  to  12  disclose 
the  presence of prohibited substances  referred  to  in Articles 2  and  3,  Member 
States shall ensure  that the  substances  concerned  are placed  under official 
control until the necessary sanctions are taken. .  I 
·~ 
I 
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Article 14 
1.  Where  the  findings  in one  Member  State indicate  the need  for investigation 
in one  or more  other Member  States,  the  Member  State concerned shall inform 
the  other Member  States  and  the  Commission  thereof  • 
2.  In accordance with  the  procedure of Article 17,  measures  may  be  taken to 
ensure  the coordination of  the  investigations necessary in relation to  the 
presence of prohibited substances. 
Article 15 
1.  Member  States shall inform  the  Commission  annually of the details of the result 
of sampling,  examinations· and  investigations made  for the  presence  of 
residues  of substances  referred to in Article 2(a). 
t 
2.  On  the  basis of this information,  the Commission  shall report  to  the Member 
States meeting in the  Standing  Vete~inary Committee  set up  by  the  Council 
Decision of 15  October 1968  (hereinafter called  the  Committee);  if 
necessary,  in accordance with  the  procedure laid down  in Article 16, 
measures  may  be  taken to ensure  the uniform application of the controls 
laid  down  by  this Directive. 
Article 16 
1.  Where  the  procedure laid down  in this Article is to  be  used,  matters shall, 
without  delay,  be  referred by  the  chairman,  either on his initiative or at 
the  request  of a  Member  State,  to  the  Committee. 
2.  Within  the  Committee,  the votes of Member  St~tes shall be  weighted as 
provided in Article 148  of the Treaty.  The  chairman shall not vote. 
3.  The  representative of the .Commission  shall submit  a  draft of the measures 
to  be  adopted.  The  Committee  shall deliver its opinion on  such  measures 
within a  period  be  determined  by  the  chairman  in keeping with  the  urgency 
of the  question submitted for  examination.  Opinions shall be  delivered  by 
a  majority of 45  votes. 
4.  The  Commission  shall adopt  the  measures  and  implement  them  immediately 
where  they are in accordance with  the  opinion of  the  Committee.  Where  they 
are not  in accordance with  the  opinion  of the  Committee  or if no  opinion is 
delivered,  the  Commission  shall,  without delay,  propose  to  the  Council  the 
measures  to  be  adopted.  The  Council shall adopt  the measures  by  a 
qualified majority. - 9  -
If, within three months  from  the  date on  which  a  matter was  referred  to it 
the Council  has  not  adopted any measures,  the Commission  shall adopt  the 
proposed measures  and  implement  them  immediately,  save where  the  Councilhas 
decided against  these measures  by  a  simple majority. 
Article 17 
1.  Where  the  procedure  laid down  in this Article is to  be  followed,  the 
chairman shall,  without  delay,  refer the matter,  either on  his own 
initiative or at the  request of a  Member  State,  to  the  Committee. 
2.  Within  the  Committee,  the votes of Member  States shall be  weighted  as 
provided in Article 148  of the  Treaty.  The  chairman shall not vote. 
3.  The  Commission  representative shall submit  a  draft of the measures  to  be 
adopted.  The  Committee  shall deliver its opinion on  such measures  within a 
period of two  days.  Opinions shall be  delivered by  a  majority of 45  votes. 
4.  The  Commission  shall adopt  the measures  and  shall apply  them  immediately 
where  they are in accordance with the opinion of the  Committee.  Where  they 
are not in accordance with  the  opinion of the  Committee  or if no  opinion is 
delivered,  the Commission  shall,  without  delay,  propose  to  the  Council  the 
measures  to be  adopted.  The  Council shall adopt  the measures  by  a 
qualified majority. 
If,  within 15  working days  from  the  date  on  which  the proposal  was 
submitted  to it,  the  Council has  not  adopted any measures,  the  Commission 
shall adopt  the  proposed measures  and  apply  them  immediately,  save where 
the  Council has  decided  against these measures  by  a  simple majority. 11 
3.  Articles  8,  9  and  10  shall become  Articles  18,  19  and  20. 
Article 2 
Member  States shall bring into force  the laws,  regulations and  administrative 
provisions necessary to comply  with  this Directive 
- not  later than  1  July 1985  as  ~rds  the  prohi~ition of  the administration of 
Trenbolone  and  Zeranolto  farm  animals  for  fattening purposes,  in application 
of Articles  2  and  5  of  Directive 81/602/EEC,  as amended  by  Article 1(1) 
of this  Directive; 
not  later than  1  July 1986  for  the  remaining  provisions.  They  shall  forthwith 
inform  the  Commission  ihereof, r 
\ 
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Article 3 
This  Directive is addressed  to  the Member  States. 
Done  at Brussels,  For  the Council 
The  President 